Key Takeaways from this article — Amyotrophic Lateral Sclerosis (ALS) affects approximately 30,000 Americans at any given time, with about 5,000 new diagnoses each year in the US alone. — The global ALS treatment market is in an active growth phase, driven by genetic stratification, biomarker-enabled trials, and a first genotype-specific approval in 2023. — […]
Read More →
Biologics have changed the way we treat diseases. Unlike small-molecule drugs, which are made from chemical compounds with clear structures, biologics are large and complex molecules that come from living organisms. This group includes monoclonal antibodies, recombinant proteins, and the growing area of cell and gene therapy. Biologics allow for better targeting of disease pathways, […]
Read More →
The global biosimilar market is undergoing a meaningful shift toward an “analytical-first” approach, making rigorous biosimilar planning more critical than ever. Regulatory agencies increasingly accept that comprehensive analytical characterization can establish biosimilarity without requiring large Phase III trials, though this is not yet universally applied across all molecule types. This evolution comes as more than […]
Read More →
The pharmaceutical landscape from 2025 onwards will undergo a structural shift driven by the latest FDA bioequivalence guidelines (2025). These guidelines are aimed at tightening study expectations while streamlining regulatory pathways for generics. For generic developers, this evolving BE framework is not just a compliance update. Rather, the new BE framework fundamentally impacts formulation strategy, […]
Read More →
Xarelto (rivaroxaban) is a leading oral anticoagulant developed by Bayer and Janssen and accounts for about 45 percent of the direct oral anticoagulant (DOAC) market. It is widely prescribed for indications such as heart failure, thrombosis of the deep veins (DVT), lung embolism (PE), and postoperative prevention. As of 2026, the drug is at a […]
Read More →
Brivaracetam, commercially available as Briviact®, is an established antiepileptic medication approved for focal epilepsy management. It is used in conjunction with other medications to help control seizures. This drug is designed to offer pharmacologic differentiation from levetiracetam, including higher SV2A affinity and improved tolerability in select patients. Major patents for Briviact® are set to expire […]
Read More →
When patents for Reference Listed Drugs (RLDs) expire, it opens the door for generic manufacturers to offer more affordable alternatives to brand-name drugs. However, successful entry into the market requires careful preparation ahead of the patent expiration. To demonstrate that a generic drug is equivalent to its branded counterpart, companies conduct thorough clinical research. This […]
Read More →
The pharmaceutical industry is undergoing a major change as patent exclusivity expires for popular drugs, highlighting vast generic drug opportunities. This shift will open up a $236 billion opportunity for generic and biosimilar manufacturers between 2025 and 2030. This significant loss of patent protection means more than just the end of exclusive rights. It will […]
Read More →
Choosing the right country for a clinical trial, particularly in complex therapeutic diseases, is a difficult task due to its reliance on factors that databases and standard metrics cannot fully measure. When therapies involve advanced technologies like modified immune cells or genetic interventions, the analysis must extend beyond basic feasibility. It requires examining site capabilities […]
Read More →
Digital tracking devices play a pivotal role in modern clinical trials. They enable remote monitoring, enhance patient safety, and support continuous, real-time data capture. However, navigating Japan’s regulatory requirements for importing these devices can be complex and device-specific. Japan welcomes these advanced technologies, which are reshaping the design and execution of clinical trials. Therefore, it […]
Read More →